EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lifetime economic burden of hemophilia using a nationwide real-world healthcare data

Joo-Young Byun iD, Jae-Hoon Jung, Suk-Chan Jang, Jamin Lim, Mihai Park iD, Eui-Kyung Lee iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0333683 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Joo-Young Byun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Penn State College of Medicine, Hershey, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Hemophilia A, Cost of Illness, Health Care Costs, Hemophilia B. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with hemophilia require lifelong treatment, but the real-world lifetime economic burden of hemophilia remains unclear. This study aims to estimate the lifetime economic burden of hemophilia using real-world data, accounting for cost variation by disease phase and over time.

Methods

Male patients with hemophilia A (PwHa) or B (PwHb) recorded in South Korea’s Health Insurance Review and Assessment (HIRA) database from 2007 to 2022 were included. Survival was estimated using the rolling extrapolation method. A phase-specific costing approach was applied, distinguishing three phases: before hemophilic arthropathy (BH), after hemophilic arthropathy (AH), and 1 year before death (BD). Transition probabilities from BH to AH were calculated based on incidence rates of hemophilic arthropathy. Phase-specific annual costs were modeled using generalized estimating equations (GEEs), and predicted costs were multiplied by phase-specific probabilities from birth to estimated life expectancy to derive lifetime costs.

Results

Estimated life expectancy for PwHa (n = 2,624) and PwHb (n = 664) in South Korea between 2007−2022 was 76.13 and 77.54 years, respectively. The incidence rate of hemophilic arthropathy was 0.090 cases/person-year [95% confidence interval, 0.084–0.097] for PwHa and 0.080 [0.070–0.092] for PwHb, yielding transition probabilities from BH to AH of 0.086 (PwHa) and 0.077 (PwHb). Mean annual costs were highest in the BD phase, followed by AH and BH phases: PwHa (BH: $11,331; AH: $27,271; BD: $27,985); PwHb (BH: $15,567; AH: $38,659; BD: $55,985). Compared to PwHa, PwHb incurred 1.37 and 1.42 times higher BH and AH costs, respectively (p < 0.05). Estimated lifetime cost was 1.76 times higher for PwHb ($22.25 million) than PwHa ($12.62 million) in hypothetical patients born in 2000.

Conclusions

Hemophilia imposes a substantial economic burden across the lifespan, with PwHb incurring higher lifetime costs than PwHa. These real-world estimates can support more informed resource allocation and planning for hemophilia care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia ACost of IllnessHealth Care CostsHemophilia BHumansMaleRepublic of KoreaMiddle AgedAdultAgedLife ExpectancyAdolescentChildYoung AdultChild, PreschoolInfant

Autor:innen und Institutionen

  • Department of Surgery, Penn State College of Medicine, Hershey, Pennsylvania, United States of America.
  • School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.

ORCID-Profile: Joo-Young Byun, Mihai Park, Eui-Kyung Lee

Zitieren

APA

Byun, J. Y., Jung, J. H., Jang, S. C., Lim, J., Park, M., & Lee, E. K. (2025). Lifetime economic burden of hemophilia using a nationwide real-world healthcare data. PLOS One. https://doi.org/10.1371/journal.pone.0333683

Vancouver

Byun JY, Jung JH, Jang SC, Lim J, Park M, Lee EK. Lifetime economic burden of hemophilia using a nationwide real-world healthcare data. PLOS One. 2025. doi:10.1371/journal.pone.0333683

BibTeX
@article{Byun2025,
  author = {Byun, Joo-Young and Jung, Jae-Hoon and Jang, Suk-Chan and Lim, Jamin and Park, Mihai and Lee, Eui-Kyung},
  title = {Lifetime economic burden of hemophilia using a nationwide real-world healthcare data},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0333683}
}
Kostenlos starten →